ArticleArthritis research & therapy2026
Alterations in systemic and skeletal muscle myostatin regulation are most prominent at disease onset and associate with muscle-related outcomes in idiopathic inflammatory myopathies.
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundRecent findings indicate attenuated myostatin (MSTN) signalling in idiopathic inflammatory myopathies (IIM) and an inverse association between circulating MSTN and disease activity. The temporal and mechanistic relationship of these alterations to disease pathogenesis remains unclear. We therefore investigated systemic and skeletal muscle MSTN regulation in newly diagnosed patients at disease onset, after six months of therapy, and in chronic IIM.
methodsA total of 101 patients with IIM and 134 healthy controls (HC) were enrolled. Muscle biopsies were obtained from 59 newly diagnosed untreated or shortly treated patients, 19 patients after six months of therapy, 19 chronic IIM patients, and 21 HC. Serum samples and clinical data were collected during routine visits. Circulating MSTN, follistatin (FST), follistatin-like 3 (FSTL3) and activin A (ActA) were measured by ELISA. mRNA and protein expression of MSTN pathway components in muscle tissue were assessed by qPCR (TaqMan
resultsNewly diagnosed IIM patients had significantly lower circulating MSTN and higher FST levels than chronic patients and HC, whereas ActA was elevated only in chronic disease. After normalization to body cell mass, MSTN remained reduced in newly diagnosed patients and increased after six months of therapy, while FST, ActA and FSTL3 did not change significantly. LMM analysis demonstrated strong associations of FSTL3 with systemic inflammation, disease activity and reduced physical and mental health scores, predominantly in female patients. In muscle tissue, newly diagnosed patients showed increased expression of MSTN pathway genes and proteins, including MSTN, SMAD2/3 and ubiquitin-proteasome components. Multivariate analyses integrating clinical, biochemical and molecular parameters identified a latent component linking MSTN pathway activation with muscle disease activity.
conclusionEarly IIM is characterized by dissociation between reduced circulating MSTN and activation of MSTN signalling in skeletal muscle, which diminishes with treatment and disease chronicity. Circulating FSTL3 is associated with systemic inflammation, disease activity and patient-reported outcomes, with pronounced associations in female patients. These findings highlight stage- and sex-dependent alterations of the MSTN regulatory network in IIM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.